PSPetra Stieber

Petra Stieber

*This is an algorithmically generated author record based on publicly available information.

Petra Stieber has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 May 2012
      • Vol. 32  (5) , 2179-83

    Nature and dynamics of nucleosome release from neoplastic and non-neoplastic cells.

    by Stefan Holdenrieder, Frank T Kolligs, Jan Braess, Davit Manukyan, Petra Stieber

    Circulating nucleosomes are elevated in the blood of patients with malignant and non-malignant diseases. Here, we investigated the nature and the dynamics of their release in functional cell studies. Leukemia blasts were exposed to the intrinsic inducers of apoptotic cell death, cytosine arabinoside (AraC; 10 μg/ml) and etoposide (50 μg/ml), and cell death markers lactate dehydrogenase (LDH) and the nucleosomes were measured in the supernatants at 0, 24, 48, 72, and 96 hours after drug application. In addition, HepG2 cells were exposed to extrinsic apoptosis-inducing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL; 0.5 and 1.0 ng/ml) and the nucleosomes were measured in the supernatants after 0, 24, 48, and 72 hours. Finally, neutrophils preactivated by phorbol myristate acetate (PMA) were co-incubated with platelet-rich plasma (PRP) in the presence of collagen (type I; 8 μg/ml) for 15 or 30 minutes at 37°C, and the nucleosome release into the supernatant was quantified. During treatment with AraC, cell viability constantly decreased. LDH and nucleosome levels increased at 24 h and peaked at 48 h after exposure to AraC and etoposide. While LDH declined after 96 h, the nucleosomes' levels were still elevated. Similarly, nucleosomes increased dose-dependently 24 h after exposure to TRAIL and reached a peak at 48 h. After 72 h, the nucleosomes' levels decreased again. While there was only a minor release of nucleosomes from PMA-stimulated neutrophils, co-incubation with PRP resulted in a strongly increased nucleosome release after 30 minutes. Nucleosomes are released from cells stimulated intrinsically or extrinsically to undergo apoptotic cell death in a time- and dose-dependent manner. Further mechanisms of release may be their active secretion from stimulated neutrophils when co-incubated with PRP, as may be observed during bacterial inflammation and thrombosis.


    • 1 May 2010
      • Vol. 30  (5) , 1613-5

    Long-term stability of circulating nucleosomes in serum.

    by Stefan Holdenrieder, Joachim Von Pawel, Dorothea Nagel, Petra Stieber

    Circulating nucleosomes, complexes of DNA and histones, are recognized as a potential new diagnostic tool for therapy monitoring of cancer disease and as prognostic marker in other acute diseases. Because many studies are carried out retrospectively on serum samples collected earlier, we tested the stability of nucleosomes during long-term storage at -70 degrees C. Never-thawed aliquots of 154 stabilized serum samples from cancer patients which had been stored between 11/1999 and 07/2001 at -70 degrees C were analyzed by ELISA six to nine months after collection and for a second time in 11/2006, with a median interval of 64.8 months (+/-5.5 months) between the measurements. Nucleosome levels of the second measurement (median 220.0 ng/ml) were significantly lower than those of the first measurement (354.0 ng/ml; p<0.0001) exhibiting a median decrease of 32.0% (mean 29.7%+/-39.7%). Single concentrations of both measurements correlated well (R=0.92; p<0.0001). Individual courses of eight cancer patients showed a parallel downshifting of the nucleosome signal. The concordance rate of parallel increases and decreases was 89%. Retrospective studies on nucleosomes in serum can be performed if samples derive from homogeneous time intervals and preanalytical protocols are respected.


    • 1 May 2010
      • Vol. 30  (5) , 1855-62

    Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.

    by Stefan Holdenrieder, Joachim Von Pawel, Thomas Duell, Knut Feldmann, Hannelore Raith, Annette Schollen, Dorothea Nagel, Petra Stieber

    Whether thymidine kinase (TK) is considered a new diagnostic biomarker in lung cancer depends on it being superior to or adding further information to already established tumor markers. Here, we investigated its relevance in diagnosis, therapy monitoring and prognosis of patients with diverse forms of lung cancer. Pretherapeutic TK concentrations were analyzed by radioimmunoassay in serum of 181 patients with advanced lung cancer (53 small cell lung cancer (SCLC), 128 non-small cell lung cancer (NSCLC)), 40 with benign lung diseases, 44 with benign non-lung-related diseases and 29 healthy controls. Diagnostic power of TK was compared with that of established lung cancer markers carcinoembryonic antigen (CEA), cytokeratin 19-fragments (CYFRA 21-1), neuron-specific enolase (NSE) and progastrin-releasing peptide (ProGRP). Furthermore, TK courses of 29 NSCLC patients during cytotoxic chemotherapy were recorded and prognostic relevance of pretherapeutic TK levels was tested in 128 NSCLC patients. While healthy controls had low TK serum levels (median 2.5 U/l, 95th percentile 8.8 U/l), they were significantly higher in patients with lung cancer (median 4.2 U/l, p=0.014) and also in patients with benign lung diseases (median 5.7 U/l; p=0.002). Patients with lung cancer and benign lung diseases could not be separated by TK values. No noticeable difference of TK concentrations was further found in NSCLC (median 4.3 U/l) as compared with SCLC patients (median 3.7 U/l) neither in adeno cell carcinomas (median 5.4 U/l) and squamous cell carcinomas (median 3.0 U/l). In NSCLC, the best diagnostic capacity versus benign lung diseases was found for CYFRA 21-1 (AUC 88.2%), NSE (AUC 86.4%), and CEA (AUC 82.9%), while TK reached only an AUC of 45.7%. The best diagnostic profile in SCLC versus benign lung diseases was observed for NSE (AUC 93.9%) and ProGRP (AUC 85.4%), while TK did not have any diagnostic power (AUC 46.6%). Concerning therapy monitoring, TK was unable to discriminate between the various response groups, neither pretherapeutically, nor before therapy cycles 2 and 3. However, pretherapeutic TK levels showed high prognostic value for overall survival in NSCLC patients: While median survival in patients with TK levels >or=20 U/l was only 3.1 months, it was 9.0 months in patients with TK levels <20 U/l. In multivariate analyses, TK remained an independent prognostic marker, along with the clinical variables stage and performance score. Although the performance of serum TK for diagnosis and therapy monitoring of advanced lung cancer was poor, it has a promising prognostic relevance which will have to be further validated.


  • Open Access

    Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer

    by Stefan Boeck, Michael Haas, Rüdiger P. Laubender, Frank Kullmann, Christina Klose, Christiane J. Bruns, Ralf Wilkowski, Petra Stieber, Stefan Holdenrieder, Hannes Buchner, et al.

    Purpose: The clinical relevance of CA 19-9 as surrogate biomarker in advanced pancreatic cancer is a matter of debate. Experimental Design: This retrospective multicenter study included patients with histologically confirmed advanced pancreatic cancer treated with first-line therapy. Analysis of CA 19-9 was done using the Elecsys assay (Roche Diagnostics). For an analysis of CA 19-9 kinetics, at least three measurements during first-line chemotherapy had to be available. The effect of pretreatment CA 19-9 levels on time-to-progression (TTP) and overall survival (OS) was modeled by Cox proportional hazards regression. The effect of CA 19-9 kinetics was also modeled by Cox proportional hazards regression where CA 19-9 was treated as a time-varying covariate. Results: One hundred and fifteen patients from five German centers were included; 73% of them were treated within prospective clinical trials. Median TTP was 4.4 months and median OS was 9.4 months; univariate analysis indicated that pretreatment CA 19-9 [as continuous variable, log (CA 19-9)] was significantly associated with TTP [hazard ratio (HR), 1.24; P < 0.001] and OS (HR, 1.16; P = 0.002). These associations remained significant within multivariate analysis. For CA 19-9 kinetics during chemotherapy, data from 69 patients (TTP) and 84 patients (OS) were available, respectively; log (CA 19-9) kinetics after start of treatment were found to be a significant predictor for TTP in univariate (HR, 1.48; P < 0.001) and multivariate (HR, 1.45; P < 0.001) analyses, and also for OS (univariate: HR, 1.34; P < 0.001; multivariate: HR, 1.38; P < 0.001). Conclusion: Pretreatment CA 19-9 and CA 19-9 kinetics may serve as a useful serum biomarker in advanced pancreatic cancer. Clin Cancer Res; 16(3); 986–94


  • Dependence of TIMP-1 Plasma Levels on Preanalytical Specimen Handling

    by Marie Dresse, Dorothea Nagel, Eva-Maria Ganser, Gerard Davis, Barry Dowell, Robert Doss, Petra Stieber

    Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) in blood might be a helpful biomarker in various diseases. However, various authors report that TIMP-1 is dependent on preanalytical procedures. Our study was performed to determine how storage conditions and time to centrifugation influence TIMP-1. Materials and Methods: Twenty-six blood specimens were collected from each of 20 volunteers. Two specimens from each person were centrifuged/measured within 1 h after venipuncture and frozen at -80 degrees C. They were thawed once or twice within 72 h. Eight specimens were stored at 20 degrees C in daylight, 8 at 20 degrees C covered and 8 at 4 C in daylight. Four of each of these 8 specimens were mixed once a day until centrifugation. A mixed and an unmixed specimen of each group was centrifuged/measured after 3, 6, 24 and 72 h. Results: TIMP-1 increased after freeze/ thaw (p < 0.001). Mixing blood specimens more than once caused increased TIMP-1 (p < 0.001). TIMP-1 increased within 3 h of storage (p < 0.001). The increase was lower in specimens covered and refrigerated (p < 0.001). Conclusion: TIMP-1 is unstable and has to be evaluated carefully. Blood should be centrifuged directly after venipuncture. For routine application, specimen handling must be standardized and carefully followed. Research should be done on specimens handled identically. Copyright (C) 2008 S. Karger AG, Basel.


    • 26 July 2007
      • Vol. 27, 1963-8

    Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.

    by Dorit Laessig, Dorothea Nagel, Volker Heinemann, Michael Untch, Steffen Kahlert, Ingo Bauerfeind, Petra Stieber

    The aim of this study analysis was to determine the correlation between elevation of CEA and/or CA 15-3 and disease progression of metastatic breast cancer. We investigated 119 breast cancer patients who had metachronous metastases. We evaluated levels of CEA and CA 15-3 at the time of first recurrence and at every further disease progression (PD). Increasing value levels of CEA as well as CA 15-3 were found in correlation to the number of PD with a continuously increasing sensitivity in the detection of metastatic disease for each marker alone and especially in combination. At the first time of distant metastasis, CEA and CA 15-3 were above the 95th percentile of healthy individuals in 53.5% and 71.8%, respectively. During disease progression the sensitivities were: 1st PD for CEA/ CA 15-3 54.1%/ 70.6%, 2nd PD 63.5%/ 81.2% and 3rd PD 68.6%/ 90%. There is a correlation between elevation of CEA and/or CA 15-3 and disease progression, in breast cancer patients.


    • 26 July 2007
      • Vol. 27, 2041-5

    Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism.

    by Stefan Holdenrieder, Peter Eichhorn, Ulrich Beuers, Walter Samtleben, Petra Stieber, Dorothea Nagel, Andrea Peterfi, Alexander Steinle, Helmut Rainer Salih

    Proteolytic shedding of the immunostimulatory NKG2D ligands MICA and MICB from cancer cells constitutes a novel immune escape strategy that diminishes antitumor reactivity by NKG2D-bearing cytotoxic lymphocytes. In consequence, serum levels of soluble MICA and MICB are frequently found to be elevated in cancer disease. As the diagnostic potential depends strongly on the organ-specific benign diseases and is affected by diseases involved in marker metabolism, both markers were analyzed by ELISA in sera of 141 patients with hepatic autoimmune diseases (34 autoimmune hepatitis, 35 primary sclerosing cholangitis, 72 primary biliary cirrhosis), 18 patients with acute bacterial infections, 21 patients with renal insufficiency, 13 patients with cholestasis and 62 healthy individuals. Similarly to healthy controls (median sMICA < 30 pg/mL; sMICB < 30 pg/mL), low levels of both markers were generally found in sera of patients with hepatic autoimmune diseases. In contrast, significantly elevated concentrations of sMICA and sMICB were observed in sera of patients with acute infections (median sMICA 890 pg/mL; sMICB 111 pg/mL), in those with renal insufficiency (sMICA 195 pg/mL; sMICB 50 pg/mL), and in those with cholestasis (sMICA 1058 pg/mL; sMICB 146 pg/mL). While hepatic autoimmune diseases have no general impact on the amount of circulating sMICA and sMICB, acute bacterial infections, renal insufficiency and cholestasis can lead to notably elevated serum levels of the NKG2D ligands.


  • Circulating Nucleosomes in Serum

    by Stefan Holdenrieder, Petra Stieber, Heinz Bodenmüller, Martin Busch, Joachim VON Pawel, Andreas Schalhorn, Dorothea Nagel, Dietrich Seidel

    Abstract: In the nucleus of eukaryotic cells, DNA is associated with several protein components and forms complexes known as nucleosomes. During cell death, particularly during apoptosis, endonucleases are activated that cleave the chromatin into multiple oligo‐ and mononucleosomes. Subsequently, these nucleosomes are packed into apoptotic bodies and are engulfed by macrophages or neighboring cells. In cases of high rates of cellular turnover and cell death, they also are released into the circulation and can be detected in serum or plasma. As enhanced cell death occurs under various pathologic conditions, elevated amounts of circulating nucleosomes are not specific for any benign or malignant disorder. However, the course of change in the nucleosomal levels in circulation of patients with malignant tumors during chemotherapy or radiotherapy is associated with the clinical outcome and can be useful for the therapeutic monitoring and the prediction of the therapeutic efficacy.


  • Open Access

    Nucleosomes in serum of patients with benign and malignant diseases

    by Stefan Holdenrieder, Petra Stieber, Martin Busch, Georg Fertig, Andreas Schalhorn, Nikolaus Schmeller, Michael Untch, Dietrich Seidel, Heinz Bodenmüller, Heinrich Fürst

    High quantities of mono‐ and oligonucleosomes circulate in the blood of patients with malignant tumors. For their direct quantification in serum, we modified the Cell Death Detectionplus‐ELISA for its application in liquid materials. We examined sera samples from 590 persons, including 418 patients with malignant tumors, 109 patients with benign diseases and 63 healthy persons. We also observed the kinetics of the concentration of nucleosomes in serum samples from 20 patients undergoing chemotherapy and from 16 patients undergoing radiotherapy. Sera of patients with malignant tumors contained considerably higher concentrations of nucleosomes (mean = 350 arbitrary units [AU], median = 190 AU) compared with those of healthy persons (mean = 36 AU, median = 24 AU; p = 0.0001) and patients with benign diseases (mean = 264 AU, median = 146 AU; p = 0.072). Concerning the follow‐up investigations, the concentration of nucleosomes in serum increased 24–72 hr after the first application of chemotherapy and 6–24 hr after the start of radiotherapy. A subsequent decrease was often correlated with regression of the tumor. In patients undergoing chemotherapy, an increase in the baseline values of circulating nucleosomes >50%, which were determined before each new therapeutic cycle, was correlated with progression of disease; all patients with disease regression showed a decrease >50% of the baseline values. In patients undergoing radiotherapy, an early decrease of the nucleosomal concentration (≤1 day after the initial peak during therapy) to low minimum levels (≤100 AU) correlated with good clinical outcome; a late decrease (>1 day) to higher minimum levels (>100 AU) was associated with a worse clinical outcome. Thus, the concentration of nucleosomes in serum might be a useful tool for monitoring the biochemical response during antitumor therapy, especially for the early estimation of therapeutic efficacy.